



IPOPORTO

**Portuguese Oncology Institute-Porto
Research Center
Cancer Epigenetics Group**

**EU Network EpiDiaCan
Second Meeting
Porto, January 28-29, 2011**

**The meeting will be held in the main auditorium of the
Portuguese Oncology Institute-Porto (IPO), 3rd floor**

Address:

**Rua (Street) Dr. Bernardino de Almeida
(Next to the IPO Metro station)**

Tel: + 351 961906711 or + 351 22 508 4000 (ext. 5614/ 7625)

Fax: + 351 22 508 4016

Meeting program:

Friday January 28, Start at 14h00

Welcome:

President of the Administration Board of IPO - Dr. Laranja Pontes

Kleri Foniadaki & Christina Telali (Financial Coordinators):

Project Financial and Administration Issues (15 min)

Group presentation (Carmen Jerónimo, Porto) (45 min)

Carmen Jerónimo

Title of the presentation: *Sample collection update*

Rui Henrique

Title of the presentation: *Evaluation of clinical significance of histone post-translational modulators in prostate cancer biopsies*

Coffee break (15min)

Group presentation (Sir Walter Bodmer, Oxford) (1 hr)

Walter Bodmer

Title of the presentation: *Stem cells in colorectal cancer cell lines*

Neil Ashley

Title of the presentation: *EZH2 and Cancer Stem Cells*

Group presentation (Laszlo Tora, Illkirch, Strasbourg) (1 hr)

Anne Riss

Didier Devys

Laszlo Tora

Title of the presentation: *Control of the deubiquitination activity of SAGA and its role in regulating histone H2Bub at promoters of inducible genes*

Group presentation (Roland Schuele, Freiburg) (1hr)

19h30- Dinner & Visit to the Porto wine cellars

Saturday January 29, Start at 9h30

Group presentation (Alex Pintzas, Athens) (1hr)

Angelo Ferraro

Alex Pintzas

Title of presentation: *EZH2 regulates cancer cell properties*

Coffee break

Group presentation (Iannis Talianidis, Vari, Athens) (1 hr)

Haroula Kontaki

Iannis Talianidis

Title of presentation: *Gene regulation in liver*

Group presentation (Thomas Henkel, Kassel) (1 hr)

Thomas Henkel

Title of presentation: *Methylation markers in clinical samples of a neoadjuvant radiotherapy trial in rectal carcinoma*

Closing remarks

On-site lunch